Subscribe
Funding & M&A
5 min read

Central Garden & Pet's TRIXIE Deal Buys Its Way Into a Fragmented European Pet Market

Central Garden & Pet is taking majority ownership of TRIXIE Heimtierbedarf, the German manufacturer that calls itself Europe's leading pet supplies and snacks company. The deal, expected to close in the first half of Central's fiscal 2027, gives the $3.1 billion US pet care company a manufacturing and retail foothold in a fragmented European market it has largely watched from the sidelines.

Written by
The Underbite
Published on
July 27, 2026
Central Garden & Pet's TRIXIE Deal Buys Its Way Into a Fragmented European Pet Market

Central Garden & Pet is acquiring a majority interest in TRIXIE Heimtierbedarf, the German manufacturer that calls itself Europe's leading pet supplies and pet snacks company. The deal hands a $3.1 billion US consumer goods player a direct foothold in a European specialty market it has mostly watched from outside, and it does so by buying control rather than building from scratch.

Central is taking majority control of a 600-employee German manufacturer while its founder keeps a minority stake

Central Garden & Pet, listed on Nasdaq as CENT and CENTA and based in Walnut Creek, California, will hold majority ownership of TRIXIE once the transaction closes. Founder Bonnik Hansen and fellow shareholders Dirk Jessen and Volker Haak retain minority stakes rather than exiting entirely. Neither company disclosed the purchase price, the size of the majority stake, or any revenue multiple attached to the deal.

TRIXIE was founded in 1974 in Tarp, Germany, and has grown into a supplier with roughly 600 employees serving more than 30,000 retailers internationally. The company sells over 6,000 products spanning most pet categories, with close to 90 percent of sales under its own brand rather than private label or licensed lines, and it launches around 500 new products a year. Central's fiscal 2025 net sales were $3.1 billion, and the company employs more than 6,000 people across North America.

Hansen framed the deal as a capstone rather than a sale, calling it "an important milestone in TRIXIE's 50-year history." Central Garden & Pet CEO Niko Lahanas said the addition "strengthens Central's position across key European markets." The companies expect the transaction to close in the first half of Central's fiscal 2027, pending regulatory approval, which puts the timeline somewhere between roughly October 2026 and March 2027.

The deal is a bet that scale beats fragmentation in European pet supplies before a private equity buyer or rival consolidator gets there first

Central's own materials peg the addressable European market TRIXIE gives it access to at roughly 10 billion euros, and the company frames the region's specialty pet channel as fragmented, which is another way of saying no single player has locked up distribution the way Chewy and the mass retailers have in the US. That fragmentation is exactly the condition private equity has been hunting in veterinary services and pet retail domestically for several years now, and it is starting to show up on the supplies and manufacturing side of the business in Europe too.

For Central, the logic is straightforward: TRIXIE already has relationships with more than 30,000 retailers, an in-house product development engine turning out 500 new SKUs a year, and 90 percent own-brand penetration, which means Central isn't just buying distribution, it's buying a manufacturing and innovation base it doesn't have to build. That's a materially different acquisition thesis than a pure roll-up, where the buyer mostly consolidates locations and cuts overlapping costs. Here, Central is paying for TRIXIE's product pipeline and retailer trust as much as its footprint.

The structure also matters. Letting Hansen and his co-shareholders retain a minority stake is a retention play as much as a financing one: family-founded manufacturers with five-decade histories tend to carry institutional knowledge in the founder's relationships with retail buyers, and an outright buyout risks losing exactly the goodwill that makes the company worth acquiring in the first place. It's the same logic that shows up in US veterinary roll-ups when a selling doctor stays on with equity rather than walking away at close.

The timing lines up with a broader pattern: US pet companies with strong balance sheets are increasingly looking abroad for growth as the domestic market matures and price competition intensifies at retail. A European deal of this size from a company Central's scale signals that management sees more room to run overseas than in a US pet aisle that has gotten more promotional and more competitive over the past two years.

Regulatory approval, integration execution, and how rivals respond are what determine whether this bet pays off

The deal isn't closed. Regulatory approval across whatever European jurisdictions TRIXIE operates in stands between announcement and completion, and a first-half-fiscal-2027 timeline gives both companies six to nine months to get there. Deals of this size involving a German manufacturer with pan-European retail relationships typically draw at least routine competition-authority review, even without an obvious antitrust flashpoint.

Once closed, integration will be the real test. Central has a track record of bolt-on acquisitions in North America, but folding a foreign manufacturer with its own product development culture, retailer relationships, and workforce into a US-headquartered public company's reporting and operating structure is a different exercise than domestic tuck-ins. How much operational autonomy TRIXIE keeps, and whether Hansen's continued involvement is enough to preserve the retailer relationships Central is paying for, will show up in future earnings commentary rather than in this announcement.

Watch for two things in the months ahead: whether other US pet suppliers or private equity firms respond with their own European acquisitions now that Central has signaled the region is investable at this scale, and how Central talks about TRIXIE's contribution when it reports fiscal 2027 results. A quiet integration with rising European revenue would validate the thesis. Any disclosed departure of Hansen or the retained shareholders, or delayed regulatory clearance, would be the early warning signs that the retention structure isn't holding.

Update, August 10: Central Garden & Pet reported fiscal third-quarter results on August 6, its first earnings call since the TRIXIE announcement. The company raised full-year guidance despite an 8% sales drop tied to exiting a separate, unrelated distribution business, a reminder that portfolio moves elsewhere in the company are reshaping the numbers before the TRIXIE deal has even closed.

Source: Central Garden & Pet via Business Wire

See every deal in the Pet Industry M&A Tracker →

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles